Kaya Launches Aerolase Neo Elite - A Laser for Acne & Scars with up to 87% Proven Results
VMPL
New Delhi [India], May 31: Kaya, India's leading chain of dermatology clinics, exclusively brings you Aerolase, a breakthrough laser treatment for active acne and acne scars that will be available only at Kaya clinics for the year ahead. This exclusive launch reinforces Kaya's commitment to offering world-class, non-invasive dermatological solutions that are safe, effective, and inclusive. Kaya become First Multi-Clinic Brand to Introduce This Revolutionary Acne Scar Solution in India
Aerolase Neo Elite, widely recognized as the leading solution in non-invasive acne care, is now introduced by Kaya, the first multi-clinic brand in India to offer this revolutionary acne scar treatment. Utilizing a 650-microsecond, 1064-nm Nd: YAG laser, it penetrates deep to target active acne, oil glands, bacteria, and post-acne scarring without harming the skin's surface.
This FDA-cleared laser treatment is suitable for all skin types, including sensitive and darker skin tones. It requires no anesthesia, gels, or downtime. Patients feel only a gentle warm sensation during the session and can resume daily activities immediately. The device's contactless handpiece ensures maximum hygiene, making it an excellent option for acne-prone skin.
The Neo Elite offers a comprehensive approach by addressing active acne, scarring, post-inflammatory hyperpigmentation (PIH), and erythema in a single session, reducing the need for multiple treatment modalities or medications. It can also be safely used in conjunction with other therapies such as topical retinoids, oral antibiotics, or isotretinoin, without requiring patients to interrupt their current regimen. Most importantly, by effectively clearing acne and improving skin texture, the treatment significantly boosts self-esteem, with 94% of patients reporting increased confidence after completing their sessions.
Speaking about the launch, Dr. Aparna Santhanam, Head Dermatologist, & Vice President at Kaya Ltd, said, "The Aerolase Neo Elite has truly raised the bar in acne and scar treatment. It is the only laser approved for acne treatment that gives efficacious results for active acne, without the need for a host of oral medications with potential side effects. We are delighted to introduce this for the first time in India, exclusively in our clinics. Our goal is to provide effective solutions that restore skin health and renew confidence, especially for the countless acne sufferers, and this technology does that and more extremely effectively."
Highlighting Kaya's vision, Nishant Nayyar, Head of Marketing and Vice President at Kaya Ltd., remarked, "Acne remains one of the most persistent skin concerns in India, with many cases continuing into adulthood and often accompanied by post-acne pigmentation. Kaya is excited to introduce Aerolase Neo Elite, an FDA-cleared advanced laser treatment that delivers up to 87% reduction in acne lesions and 82% improvement in scarring. Safe, contactless, and effective for all skin types, this innovation reinforces our commitment to delivering breakthrough solutions that truly transform lives and restore confidence.''
With Aerolase Neo Elite, Kaya aims to deliver clearer, smoother, healthier skin through a technology-driven, patient-first approach. This innovation reinforces Kaya's position at the forefront of dermatological care, offering holistic solutions that enhance not just appearance but also confidence.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
an hour ago
- Indian Express
Fungus on items, stagnant water: Maharashtra FDA suspends food licence of Zepto's Dharavi outlet
The Maharashtra Food and Drug Administration (FDA) has suspended the food business licence of the Dharavi outlet of Kiranakart Technologies Pvt Ltd, the parent company of Zepto, following an inspection on Saturday which revealed multiple violations of food safety norms at the distribution centre. The inspection was carried out by food safety officer Ram Bodke, based on directions from Minister of State for FDA Yogesh Kadam, and under the supervision of Mangesh Mane, Joint Commissioner, Food. The probe unearthed a slew of violations at the distribution centre under the Food Safety and Standards Act, 2006, and the accompanying licensing regulations, the FDA claimed. Among the most serious findings included the alleged visible fungal growth on food items, stagnant and clogged water near storage areas which indicated poor sanitation, improper cold storage with temperatures not maintained as per norms, and wet, unclean floors and food products stored haphazardly, including directly on the ground, according to the regulatory authority. The FDA also claimed that expired food products were kept alongside fresh stock, without clear separation. In response, Anupamaa Balasaheb Patil, Assistant Commissioner, Food, issued an immediate suspension order under section 32(3) of the Food Safety Act and Regulation 2.1.8(4) of the Licensing and Registration Rules. The order mandates that the facility cannot resume operations until it demonstrates full compliance and receives formal clearance from the licensing authority. An official statement from Zepto on the matter is awaited. The FDA said that the action is part of its ongoing crackdown on unsafe food practices. 'Public health cannot be compromised. We are committed to strict and transparent enforcement,' said Rajesh Narvekar, Commissioner, FDA. The licence will remain suspended until the Dharavi facility clears a follow-up inspection and receives formal reinstatement approval from the FDA. The FDA is the state's principal regulatory authority dedicated to ensuring the safety, quality, and compliance of food products, medicines, and cosmetics. Operating under the Department of Medical Education and Pharmaceuticals, it is responsible for implementing and enforcing various legislations pertaining to food safety and drugs.
India Today
15 hours ago
- India Today
Fungus on food, expired goods: Zepto's Dharavi licence suspended over lapses
The Maharashtra Food and Drug Administration (FDA) has suspended the food business license of Kiranakart Technologies Pvt. Ltd., which operates under the brand name Zepto, following serious food safety violations at its Dharavi warehouse. The action was taken after an inspection revealed fungal growth on food items, expired products, and unhygienic storage inspection was prompted by information from Minister of State for Food and Drug Administration Yogesh Kadam, and was carried out under the supervision of Joint Commissioner (Food) Mangesh Mane. Food Safety Officer Ram Bodke, acting on the directive, found multiple violations of the Food Safety and Standards Act, 2006, and related regulations during the visit to the Zepto serious lapses were observed, including:Fungal growth on certain food articlesStorage of products near clogged or stagnant water, indicating poor hygieneCold storage temperatures not maintained as per regulatory standardsDisorganised storage of food items, some kept directly on wet and filthy floorsExpired food products found not clearly segregated from non-expired stockIn response to the violations, an immediate suspension order under Section 32(3) of the Food Safety and Standards Act, 2006, was issued by Assistant Commissioner (Food) Anupamaa Balasaheb Patil. The suspension will remain in effect until Zepto achieves full regulatory compliance and receives clearance from the competent to the action, a Zepto spokesperson said the company had initiated an internal review and was cooperating fully with authorities. "At Zepto, maintaining the highest standards of food safety and hygiene is non-negotiable. We have already initiated an internal review and are working closely with the concerned authorities to ensure full and swift compliance. We are committed to rectifying the lapses identified, and strengthening our processes to provide the best and safest quality of products to our consumers. We are taking all necessary corrective measures to resume operations in accordance with regulatory obligations and applicable laws at the earliest," the spokesperson Reel
Time of India
16 hours ago
- Time of India
Woman sheds 4 stone(25 kilos) in 4 months on Mounjaro, then suffers liver failure—how the drug works and its risks
Aimee Chapman, 34, from Southampton, lost four stone in just four months using Mounjaro—but her rapid transformation came at a devastating cost. The former waitress was admitted to intensive care last summer with liver failure and a perforated oesophagus, complications doctors directly linked to the weight-loss injection. Tired of too many ads? go ad free now Chapman had purchased Mounjaro from a major online pharmacy in March 2024, hoping that losing weight would help her be 'taken more seriously' by doctors after being diagnosed with fibromyalgia, a chronic pain disorder. At first, the results were everything she hoped for. But just a few months in, her health began to unravel. "I couldn't really do much. I was only eating a couple of times a week," she said. "I stopped being able to walk. I would take a couple of steps and have to stop. Then I couldn't stop being sick. I was throwing up all the time and started throwing up blood. I was sick between 50 and 60 times." Chapman collapsed multiple times. "My husband came home and found me passed out on the hallway one night," she said. Initially, she believed it was a virus. 'I was in a bit of denial about it being linked to the jab because I was fine up until now.' It wasn't until she experienced severe chest pains that she went to Winchester Hospital A&E. There, doctors discovered a hole in her oesophagus—allowing air to leak around her heart and lungs. As her blood pressure and potassium levels dropped, she was transferred to intensive care at Southampton General Hospital, where doctors found her liver was 'failing.' A transplant was considered. "They had said it was down to the weight-loss jab but they didn't know why or how to fix it," she said. "I was terrified. It all happened so quickly… I was told the hole in the oesophagus can kill people and I may have needed a new liver. Tired of too many ads? go ad free now They said I could've died." Though her condition was stabilized within two weeks, her ordeal continued. By September, she began losing large clumps of hair—eventually diagnosed as a vitamin B12 deficiency. 'It kept happening and the handfuls kept getting bigger. I would be so sad,' she said. 'My hair was such a massive part of my identity and to cut it off just felt really traumatic.' While she doesn't want to 'tell people what they can and can't take,' Chapman says, 'I regret ever taking them. I'd say to other people thinking about trying them, don't do it online, go through your doctor who can give you blood tests and check how you're doing.' What exactly is Mounjara? According to Mounjaro (tirzepatide) is a once-weekly injection primarily prescribed to manage type 2 diabetes by lowering blood sugar levels. In addition to its intended purpose, the medication is also known to promote weight loss. It is meant to be used alongside a healthy diet and regular exercise. The U.S. Food and Drug Administration (FDA) approved Mounjaro on May 13, 2022, and got a at the end of 2023 for weight loss in adults. Currently, there is no generic version available. Tirzepatide is sold under two brand names—Mounjaro and Zepbound—both manufactured by Eli Lilly and Company. While they contain the same active ingredient, they are approved for different medical uses. How does Mounjaro work? According to the National Library of Medicine, mounjaro (tirzepatide) works through a unique dual-action approach by targeting two key gut hormone receptors. Here's how it helps manage blood sugar and promote weight loss: Activates Two Hormone Receptors Slows Down Stomach Emptying Controls Appetite Increases Satiety Influences Brain Reward Pathways What are the known side effects? Like many medications in its class, Mounjaro is associated with a range of side effects, most of which involve the gastrointestinal (GI) system. According to Eli Lilly and Co. and the U.S. Food and Drug Administration ( ), the most commonly reported side effects include: Nausea Vomiting Diarrhea Constipation Abdominal pain or discomfort Decreased appetite Indigestion or heartburn
